PEGBIO CO-B (02565) announced that its Vepetide Injection has been included in the public notice for the second batch of 2026 reference drug pre-communication supplementary drugs, as published by the National Healthcare Security Administration on May 27, 2026. The company's submitted materials for Vepetide Injection have been confirmed to meet the application requirements for the 2026 second batch reference drug pre-communication process following feedback. The public notice period is from May 27, 2026, to June 2, 2026. This inclusion in the supplementary public notice marks a phased progress for Vepetide Injection in the national reimbursement reference drug pre-communication process, which will facilitate the orderly advancement of subsequent work related to reference drug confirmation, national reimbursement list access, and payment management. The board of directors believes this progress reflects the continuous advancement of the company's core product in post-market access work and will also help enhance the product's future clinical accessibility, payment accessibility, and foundation for commercial promotion. Vepetide Injection is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently developed by the company. It has been approved by the National Medical Products Administration for glycemic control in adults with type 2 diabetes. The product features a fixed-dose, once-weekly administration regimen without the need for dose titration, offering a clear usage pathway, good patient compliance, and suitability for long-term chronic disease management. The company will continue to advance the market access, academic promotion, and commercial implementation of Vepetide Injection to further enhance the product's clinical value and accessibility for patients with type 2 diabetes in China. Shareholders and potential investors should note that this public notice represents a phased development within the national reimbursement reference drug pre-communication procedures and does not equate to the product having completed reference drug confirmation, been included in the national reimbursement drug list, or secured any final payment arrangements. Any subsequent developments remain subject to official notifications, announcements, or final outcomes from the relevant authorities.